NCT06175000
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06175000
Title Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Providence Health & Services
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Memorial Sloan Kettering Cancer Center NOT_YET_RECRUITING New York New York 10065 United States Details
Cleveland Clinic NOT_YET_RECRUITING Cleveland Ohio 44195 United States Details
Providence Health & Services; Providence Neurological Specialties RECRUITING Portland Oregon 97225 United States Details
Pennsylvania State University RECRUITING Hershey Pennsylvania 17033 United States Details
University of Vermont RECRUITING Burlington Vermont 05405 United States Details
University of Virginia RECRUITING Charlottesville Virginia 22903 United States Details
Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute RECRUITING Seattle Washington 98122 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field